Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03601819 · ClinicalTrials.gov registry record · Phase 1
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03601819 is a Phase 1 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT03601819, a Phase 1 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.
Interventions
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2020-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03601819
The ClinicalTrials.gov registry entry for NCT03601819 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pacritinib is the first listed.
NCT03601819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03601819 about?
NCT03601819 is a clinical study titled "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders". This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.
What is the current status of trial NCT03601819?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-05-15. Estimated completion is 2020-07-17.
What interventions are being tested in trial NCT03601819?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT03601819?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.